$0.71 Earnings Per Share Expected for DexCom, Inc. (NASDAQ:DXCM) This Quarter

Brokerages forecast that DexCom, Inc. (NASDAQ:DXCMGet Rating) will announce earnings of $0.71 per share for the current fiscal quarter, Zacks reports. Eight analysts have issued estimates for DexCom’s earnings, with the lowest EPS estimate coming in at $0.52 and the highest estimate coming in at $0.87. DexCom reported earnings per share of $0.76 in the same quarter last year, which suggests a negative year over year growth rate of 6.6%. The firm is scheduled to announce its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that DexCom will report full year earnings of $3.28 per share for the current financial year, with EPS estimates ranging from $3.10 to $3.47. For the next year, analysts forecast that the firm will post earnings of $4.61 per share, with EPS estimates ranging from $3.90 to $5.69. Zacks’ EPS averages are an average based on a survey of research analysts that cover DexCom.

DexCom (NASDAQ:DXCMGet Rating) last announced its quarterly earnings data on Thursday, April 28th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.52 by ($0.20). DexCom had a net margin of 8.23% and a return on equity of 12.42%. The firm had revenue of $628.80 million during the quarter, compared to the consensus estimate of $623.97 million. During the same period last year, the business earned $0.33 earnings per share. The business’s revenue was up 24.5% compared to the same quarter last year.

A number of brokerages have recently commented on DXCM. Canaccord Genuity Group cut their price target on shares of DexCom from $525.00 to $500.00 in a report on Friday, April 29th. Zacks Investment Research lowered shares of DexCom from a “hold” rating to a “sell” rating and set a $452.00 target price on the stock. in a report on Tuesday, February 1st. Piper Sandler decreased their price target on shares of DexCom from $725.00 to $480.00 in a research note on Friday, April 29th. StockNews.com initiated coverage on shares of DexCom in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Finally, Robert W. Baird decreased their target price on shares of DexCom from $625.00 to $560.00 in a research report on Friday, February 11th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $541.65.

DexCom stock traded up $5.11 during mid-day trading on Friday, reaching $321.23. The company had a trading volume of 824,296 shares, compared to its average volume of 910,828. DexCom has a fifty-two week low of $302.61 and a fifty-two week high of $659.45. The company has a current ratio of 5.27, a quick ratio of 4.79 and a debt-to-equity ratio of 0.90. The company has a market cap of $31.52 billion, a P/E ratio of 155.18, a P/E/G ratio of 5.55 and a beta of 1.05. The business has a fifty day simple moving average of $436.34 and a 200 day simple moving average of $477.16.

Shares of DexCom are set to split before the market opens on Friday, June 10th. The 4-1 split was announced on Friday, March 25th. The newly created shares will be payable to shareholders after the market closes on Thursday, June 9th.

In related news, EVP Barry J. Regan sold 1,106 shares of the company’s stock in a transaction that occurred on Tuesday, March 29th. The shares were sold at an average price of $500.00, for a total transaction of $553,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Steven Robert Pacelli sold 250 shares of the company’s stock in a transaction that occurred on Wednesday, February 23rd. The shares were sold at an average price of $394.33, for a total transaction of $98,582.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 4,009 shares of company stock worth $1,783,689. Corporate insiders own 0.41% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Rise Advisors LLC purchased a new stake in shares of DexCom during the 4th quarter valued at approximately $26,000. Riverview Trust Co bought a new stake in DexCom during the 1st quarter worth approximately $25,000. Equitec Proprietary Markets LLC bought a new stake in DexCom during the 4th quarter worth approximately $29,000. American National Bank bought a new stake in DexCom during the 4th quarter worth approximately $37,000. Finally, Benjamin F. Edwards & Company Inc. bought a new stake in DexCom during the 4th quarter worth approximately $37,000. Institutional investors own 93.26% of the company’s stock.

DexCom Company Profile (Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Featured Stories

Get a free copy of the Zacks research report on DexCom (DXCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.